Join Swanson Reed, Aston Ryan Malcolm and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.
You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.
On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.
|7:00am – 7:30am:||Session 1: Protecting Intellectual Property (IP)||Joe Seisdedos|
|7:30am – 8:00am:||Session 2: IP & Relevant Tax Considerations||David Coutts|
|8:00am – 8:30am:||Session 3: R&D Tax Incentives||Adam Rogers|
|8:30am – 9:00am:||Session 4: Panel Q&A and Networking Opportunity|
|Joe Seisdedos||David Coutts||Adam Rogers|
|View Joe’s bio||View David’s bio||View Adam’s bio|
Register Before: Friday 13th June
Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.
Contact Amy Nolan for more information:
Ph: 03 9018 5778
Mob: 0435 713 493
Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.
InnovationAus this week has reported on concerns raised by advocacy group Fintech Australia in respect of the application of the R&D Tax Incentive to software activity. The concerns were raised in the group’s submission to the Select Committee on Australia as a Technology and Financial Centre, and a summary of points raised include: concern that regulators’ interpretations of “activities” and “experiments” under the scheme are restrictive to software claims and lead to many tech firms not accessing the incentive; concern that […]
In the May federal budget, the Australian Government announced that it will introduce a patent box for eligible income associated with new patents in the medical and biotechnology sectors. The patent box will apply to companies for income years commencing on or after 1 July 2022, and for new Australian patents since budget night. The aim of such a policy is to encourage companies to base their medical and biotechnology R&D activity in Australia and to retain associated patent […]